121 related articles for article (PubMed ID: 10756361)
1. Amifostine in the treatment of low-risk myelodysplastic syndromes.
Grossi A; Fabbri A; Santini V; Leoni F; Nozzoli C; Longo G; Pagliai G; Ciolli S; Rossi Ferrini P
Haematologica; 2000 Apr; 85(4):367-71. PubMed ID: 10756361
[TBL] [Abstract][Full Text] [Related]
2. [Application of bioinformatics analysis to optimize amifostine combination therapeutic regimen of myelodysplastic syndrome].
Lu XC; Yang B; Zhu HL; Fan H; Li SX; Liu Y; Yao SQ
Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(26):1834-7. PubMed ID: 19953928
[TBL] [Abstract][Full Text] [Related]
3. Amifostine plus erythropoietin in a patient with low-risk myelodysplastic syndrome.
Musch E; Malek M; Chrissafidou A
Ann Hematol; 2003 Apr; 82(4):244-6. PubMed ID: 12707729
[TBL] [Abstract][Full Text] [Related]
4. Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response.
Viniou N; Terpos E; Galanopoulos A; Kritikou-Griva E; Akel S; Michalis E; Apostolidou E; Georgiadou D; Kouraklis A; Parharidou A; Kokkini G; Symeonidis A; Anagnostopoulos NI; Christakis JI; Tasiopoulou A; Loukopoulos D; Yataganas X
Ann Hematol; 2002 Apr; 81(4):182-6. PubMed ID: 11976818
[TBL] [Abstract][Full Text] [Related]
5. Preliminary results of amifostine administration in combination with recombinant human erythropoietin in patients with myelodysplastic syndromes.
Tsiara SN; Kapsali HD; Panteli K; Christou L; Bourantas KL
J Exp Clin Cancer Res; 2001 Mar; 20(1):35-8. PubMed ID: 11370827
[TBL] [Abstract][Full Text] [Related]
6. Changes in hemopoietic precursors after treatment of low-risk myelodysplasia with amifostine.
Ribeiro E; Lima CS; Metze K; Souza CA; Lorand-Metze I
In Vivo; 2003; 17(2):181-4. PubMed ID: 12792983
[TBL] [Abstract][Full Text] [Related]
7. Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes.
Grossi A; Musto P; Santini V; Balestri F; Fabbri A; Falcone A; Sanpaolo G
Haematologica; 2002 Mar; 87(3):322-3. PubMed ID: 11869946
[TBL] [Abstract][Full Text] [Related]
8. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
9. [Myelodisplasic syndromes diagnosed in a geriatric hospital: morphological profile in 100 patients].
Dewulf G; Gouin I; Pautas E; Gaussem P; Chaïbi P; Andreux JP; Siguret V
Ann Biol Clin (Paris); 2004; 62(2):197-202. PubMed ID: 15047472
[TBL] [Abstract][Full Text] [Related]
10. Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia.
Bessho M; Jinnai I; Matsuda A; Saito M; Hirashima K
Int J Cell Cloning; 1990 Nov; 8(6):445-58. PubMed ID: 2273298
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
12. Amifostine promotes hemopoietic progenitor cell mobilization in patients with myelodysplastic syndrome.
Arboscello E; Botta M; Lerza R; Bogliolo G; Clavio M; Miglino M; Mencoboni M; Pannacciulli I
Anticancer Res; 2002; 22(3):1819-24. PubMed ID: 12168875
[TBL] [Abstract][Full Text] [Related]
13. Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes.
Schanz J; Jung H; Wörmann B; Gassmann W; Petersen T; Hinke A; Haase D
Leuk Res; 2009 Sep; 33(9):1183-8. PubMed ID: 19411105
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome.
List AF; Brasfield F; Heaton R; Glinsmann-Gibson B; Crook L; Taetle R; Capizzi R
Blood; 1997 Nov; 90(9):3364-9. PubMed ID: 9345018
[TBL] [Abstract][Full Text] [Related]
15. Activity of sirolimus in patients with myelodysplastic syndrome--results of a pilot study.
Platzbecker U; Haase M; Herbst R; Hänel A; Voigtmann K; Thiede CH; Mohr B; Schleyer E; Leopold T; Orth M; Hänel M; Ehninger G; Bornhäuser M
Br J Haematol; 2005 Mar; 128(5):625-30. PubMed ID: 15725083
[TBL] [Abstract][Full Text] [Related]
16. The soluble transferrin receptor in dysplastic erythropoiesis in myelodysplastic syndrome.
Metzgeroth G; Rosée PL; Kuhn C; Schultheis B; Dorn-Beineke A; Hehlmann R; Hastka J
Eur J Haematol; 2007 Jul; 79(1):8-16. PubMed ID: 17532764
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation.
Hartmann JT; von Vangerow A; Fels LM; Knop S; Stolte H; Kanz L; Bokemeyer C
Br J Cancer; 2001 Feb; 84(3):313-20. PubMed ID: 11161394
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
19. Amifostine (Ethyol) as modulator of hepatic and biliary toxicity from intraarterial hepatic chemoembolization: results of a phase I study.
Fiorentini G; Giovanis P; Leoni M; De Giorgi U; Cariello A; Dazzi C; Caldeo A
Hepatogastroenterology; 2001; 48(38):313-6. PubMed ID: 11379297
[TBL] [Abstract][Full Text] [Related]
20. Effects of amifostine in a patient with an advanced-stage myelodysplastic syndrome.
Yilmaz A; Kaufmann CC; Binder C; Wörmann B; Haase D
Ann Hematol; 2001 Jan; 80(1):53-7. PubMed ID: 11233778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]